-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
Tight UK security ahead of match against Israeli club
-
Ethiopia's Afar region says attacked by Tigray forces
-
Nancy Pelosi, Democratic giant, Trump foe, first woman House speaker, to retire
-
Israel strikes Hezbollah targets in Lebanon
-
Burger strikes as South Africa restrict Pakistan to 269-9 in second ODI
-
Stocks slip as investors weigh earnings, tariffs
-
Police say 19 held after raid at Swedish start-up Stegra to be deported
-
Kante returns as France seek to clinch World Cup berth
-
Marcus Smith starts at full-back as England ring changes for Fiji
-
Kolisi 100th Test 'no distraction' for Erasmus' South Africa
-
Teetering Belgian government given more time to agree budget
-
Merz backs EU plan to protect steel sector from Chinese imports
-
New Zealand make Scotland changes after Barrett brothers' injuries
-
'Roy of the Rovers story' -- Farrell handed Ireland debut for Japan Test
-
Stones backs Man City team-mate Foden to pose England dilemma for Tuchel
-
Djokovic to face Alcaraz in ATP Finals groups
-
Facing climate 'overshoot', world heads into risky territory
-
Springbok skipper Kolisi to play 100th Test against France
-
Typhoon Kalmaegi hits Vietnam after killing 140 in Philippines
-
Bank of England leaves rate unchanged before UK budget
-
Germany recall Sane, hand El Mala debut for World Cup qualifers
-
India thump Australia to take 2-1 lead in T20 series
-
Cameroon's Biya, world's oldest president, sworn in for 8th term
-
Flick holding firm on Barca high line despite defensive woes
-
Battered US businesses eye improved China trade at Shanghai expo
-
France opt for Le Garrec as Dupont replacement for 'best team ever' South Africa
-
Drugmaker AstraZeneca profit jumps as US business grows
-
'Vibe coding' named word of the year by Collins dictionary
-
Vietnam evacuates thousands from coast ahead of Typhoon Kalmaegi
-
European stocks fall after gains in Asia, US
-
MotoGP legend Agostini admires Marc Marquez's 'desire to win'
-
Nepal searches for avalanche victims
-
Hezbollah rejects any negotiations between Lebanon and Israel
-
Chapman blitz leads Black Caps to tight T20 victory over West Indies
-
France urges EU to sanction Shein platform
-
France opt for Le Garrec as Dupont replacement for South Africa Test
-
Turmoil in tiaras at Miss Universe pageant in Thailand
-
Probe into Thales defence group looking at Indonesian contract
-
US to cancel flights as longest govt shutdown drags on
-
Home in Nigeria, ex-refugees find themselves in a war zone
-
Doncic's Lakers hold off Wembanyama's Spurs, Blazers silence Thunder
-
For Turkey's LGBTQ community, draft law sparks existential alarm
-
Musk's $1 trillion pay package to face Tesla shareholder vote
-
Tonga rugby league star out of intensive care after seizure
-
Argentine ex-president Kirchner goes on trial in new corruption case
-
Dams, housing, pensions: Franco disinformation flourishes online
-
Endo returns as Japan look to build on Brazil win
-
Franco captivates young Spaniards 50 years after death
-
German steel industry girds for uncertain future
RFK Jr panel votes against ingredient targeted by anti-vaxxers
A newly appointed US medical panel voted Thursday to oppose the use of a vaccine ingredient long targeted by Health Secretary Robert F. Kennedy Jr. over debunked claims it causes autism.
Thimerosal, a preservative that prevents bacterial and fungal contamination in multidose vials, has been extensively studied, with authorities including the World Health Organization finding no evidence of harm beyond minor injection-site reactions.
Though thimerosal is now rarely used in US vaccines, its inclusion on the Advisory Committee on Immunization Practices' agenda alarmed experts, who say the move has effectively embedded anti-vaccine talking points into national policy.
Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 ACIP members earlier this month, accusing them of conflicts of interest.
Across three votes, his new handpicked panelists recommended that thimerosal be removed from influenza vaccines for children, pregnant women and finally all adults.
Cody Meissner, a professor of pediatrics at Dartmouth University and the lone voice of dissent, said: "The risk from influenza is so much greater than the nonexistent risk as far as we know from thimerosal," adding that he was worried about the decision's global impact.
Although 96 percent of US flu vaccines in the 2024-2025 season did not contain thimerosal, the preservative remains important globally, particularly in multidose vials that must be punctured repeatedly, raising the risk of contamination.
Thimerosal contains an artificial form of mercury called ethylmercury that is cleared from the body far more quickly than the form of the substance found in nature.
US manufacturers voluntarily removed it from most pediatric vaccines in 2001.
- 'Platform for anti-vaccine talking points' -
"The fact that it's being brought up again -- something that's already been adjudicated -- shows how the ACIP is becoming a platform for anti-vaccine talking points to come back to life long after most of us thought they'd been put to rest," Amesh Adalja, an infectious disease specialist at Johns Hopkins University, told AFP.
Ahead of the vote, Lyn Redwood, a nurse and former leader of the anti-vaccine group Children's Health Defense, which Kennedy once chaired, was invited to present arguments against thimerosal.
A previous version of her slideshow, which was posted online before the meeting, was removed without explanation after it was found to contain a fabricated citation, likely the result of an AI hallucination.
The Centers for Disease Control and Prevention had prepared a rebuttal to Redwood's presentation, but it was mysteriously removed from the meeting website.
Robert Malone, a new panel member known for spreading misinformation during the Covid-19 pandemic, including promoting the antiparastic drug ivermectin to treat the virus, later said the CDC document had not been approved by the Office of the Secretary.
Earlier in the meeting, the same panel voted to recommend a new antibody treatment against RSV, a common respiratory illness and the leading cause of infant hospitalization in the United States.
Clesrovimab, recently approved by the Food and Drug Administration, is administered as a single shot to newborns and young babies entering their first respiratory syncytial virus season.
Marketed as Enflonsia by Merck, it was shown in clinical trials to significantly reduce RSV infections and hospitalizations among infants.
L.Davis--AMWN